publicações selecionadas
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
- Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel
- Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
- Fatores preditivos de resposta aos inibidores de tirosino-quinase de segunda geração em pacientes com diagnóstico de leucemia mielóide crônica resistente ao imatinibe
- AS RESPOSTAS MOLECULARES AOS 3 E 6 MESES APÓS TROCA PARA O INIBIDOR DE TIROSINO QUINASE DE SEGUNDA GERAÇÃO SÃO COMPLEMENTARES E PREDITIVAS DE PROGNÓSTICO A LONGO PRAZO EM PACIENTES COM LEUCEMIA MIELÓIDE CRÔNICA QUE FALHAM AO IMATINIBE
- Vox Sanguinis International Forum on transfusion services' response to COVID-19: Summary
- Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
- Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
- Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
